Literature DB >> 6415666

Sodium salicylate interferes with the inhibitory effects of aspirin and indomethacin on human platelets.

M L Dahl, T Puustinen, P Uotila.   

Abstract

The interference of sodium salicylate with the effects of acetylsalicylic acid (ASA, aspirin) and indomethacin on arachidonic acid-induced platelet aggregation and thromboxane formation was studied in human platelet rich plasma. ASA and indomethacin suppressed both aggregation and the concomitant formation of thromboxane B2 whereas sodium salicylate alone had no significant effect on these parameters of platelet function. It did, however, partially prevent the inhibitory effects of ASA and indomethacin on platelet aggregation when it was added to platelet rich plasma before ASA or indomethacin. The inhibition of thromboxane formation by indomethacin was also prevented by sodium salicylate. When sodium salicylate was added to platelet rich plasma after ASA or indomethacin it did not modify the effects of these drugs. The present study indicates that sodium salicylate interferes with the effects of ASA and indomethacin on human platelet cyclo-oxygenase in vitro.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6415666     DOI: 10.1016/0262-1746(83)90064-1

Source DB:  PubMed          Journal:  Prostaglandins Leukot Med        ISSN: 0262-1746


  3 in total

1.  Effects of salicylic and acetylsalicylic acid alone and in combination on platelet aggregation and prostanoid synthesis in man.

Authors:  B Rosenkranz; C Fischer; C O Meese; J C Frölich
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

Review 2.  Platelets in allergy. Assays and interpretation.

Authors:  M Joseph
Journal:  Clin Rev Allergy       Date:  1988

3.  Influence of intravenous acetylsalicylic acid and sodium salicylate on human renal function and lithium clearance.

Authors:  I W Reimann; E Golbs; C Fischer; J C Frölich
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.